Vir Biotechnology VIR 深 沪
已收盘 02-06 16:00:00 美东时间
7.19
+0.270
+3.90%
华盛通- 最 高7.3957
- 今 开7.06
- 成交量 186.48万股
- 最 低 7.04
- 昨 收 6.92
- 总市值 10.00亿
- 52周最高 9.98
- 市盈率 静 --
- 换手率 1.34%
- 52周最低 4.155
- 委 比 97.37%
- 总股本 1.39亿
- 历史最高 141.01
- 量 比 1.24
- 振 幅 5.14%
- 历史最低 4.155
- 每 手 1
- 风险率 1.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多U.S. RESEARCH ROUNDUP- Ametek, Coca-Cola, Pepsico
U.S. RESEARCH ROUNDUP- Ametek, Coca-Cola, Pepsico Feb 4 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Ametek, Coca-Cola and Pepsico, on Wednesday. HIGHLIGHTS * Ametek AME.N : RBC raises target price to $257 from $229 *
02-04 14:59
Vir Biotechnology Director Vicki L. Sato Reports Disposal of Common Shares
Vir Biotechnology Director Vicki L. Sato Reports Disposal of Common Shares Vicki L. Sato, Director at Vir Biotechnology Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (P
02-04 01:29
Vir Biotech Reports Strong New Results For Experimental Hepatitis Drug, Shares 2026 Outlook
Vir Biotechnology, Inc. (NASDAQ:VIR) today provided key program updates, including new positive data from the ongoing SOLSTICE Phase 2 trial in chronic hepatitis delta (CHD). Participants receiving the combination
01-12 21:12
美股大行评级 | 潜在涨幅1391.05%！Maison Solutions获Ascendiant Capital升目标价至4.5美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Maison Solutions"买入"评级，目标价从4.25美元升至4.5美元；HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从39美元升至50美元
2025-12-31 10:25
HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $15 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $15 price target.
2025-12-30 21:33
Vir Biotechnology Secures Licensing Deal with Norgine
Vir Biotechnology ( ($VIR) ) just unveiled an update. On December 16, 2025, Vir...
2025-12-17 05:50
Vir Biotechnology Licenses Hepatitis Delta Therapy To Norgine In Up To €550 Million Deal, Secures €55 Million Upfront, And Up To €495 Million In Clinical, Regulatory And Sales Milestones, Along With Tiered, Mid-Teen To High-Twenties Percent Royalties On Net Sales
– Vir Biotechnology to receive EUR 55 million initial reimbursement payment upon closing, and up to EUR 495 million in clinical, regulatory and sales milestones, along with tiered, mid-teen to high-twenties percent
2025-12-17 05:07
Vir Biotechnology Doses First Patient In Part 3 Of Its Phase 1 Trial Evaluating VIR-5500
– Phase 1 clinical trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5500 in combination with androgen receptor pathway inhibitors in first-line mCRPC– Clinical trial builds on
2025-10-10 04:09
美股大行评级 | 潜在涨幅432.99%！维持"投机性买入"评级，Unicycive Therapeutics获机构升目标价至21美元
今日重点评级关注：Benchmark：维持Unicycive Therapeutics"投机性买入"评级，目标价从3美元升至21美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从17美元升至25美元
2025-09-16 09:48
HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $15 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $15 price target.
2025-09-16 02:39
